Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It was about the MAX Expo
Keith Nalepka
? @keith_nalepka
4h4 hours ago
Great to be a part of http://www.maxhealthexpo.com Sree is a presenter and we look forward to showing how Actipatch can drive outcomes in the Payers/reimbursement space.
Only after 90 days should it be a concern as far as approval goes. On a moral level it's borderline criminal that ActiPatch hasn't been approved already. Every day wasted by the FDA, is another day someone taking opioids gets hooked and has their life ruined and becomes a drag on the healthcare system and the country.
Trump want to sue opioid makers.
WASHINGTON (AP) — President Donald Trump is asking Attorney General Jeff Sessions to file a federal lawsuit against certain companies that supply and manufacture opioids.
Speaking during a Cabinet meeting Thursday, Trump said he's directing Sessions to file a separate lawsuit, rather than joining existing lawsuits filed by states affected by the spread of the often-lethal, highly-addictive drugs.
Trump is asking Sessions to look out for opioids coming into the U.S. from China and Mexico, saying those countries are "sending their garbage and killing our people."
Trump added: "It's almost a form of warfare."
It was not immediately clear if or when a federal suit would be filed. A barrage of suits have been filed nationwide against distributors and manufacturers in recent months amid the opioid epidemic.
From Paul
With the NHS covering ActiPatch, do physicians even know it exists to prescribe it?
We have stopped over-the-counter sales and we are focused on organizing detailing of the physicians.
I will be disappointed with anything under 388. I expect to be disappointed. With a slow B Braun rollout, sales moved to behind the counter in the UK and UK doctors not knowing ActiPatch exists we will probably need to wait til 2019 to see good improvement. We will be news dependent for a while yet, luckily we have full clearance and Dr Scholls most likely in the near term.
Nice move Bill. I had ordered another spare as well. The one seller seems to have more stock now. It's nice to have a few around the house for personal use or for when a friend has an injury.
I've turned on several people to ActiPatch and will continue to do so. Now if we could get the company to do it I would feel better.
Unfortunately, I don't think many docs in the UK know about ActiPatch to even prescribe it. Paul said,"We have stopped over-the-counter sales and we are focused on organizing detailing of the physicians." Widespread adoption may be a while off. Hopefully we will see joint replacement scripts rise meaningfully in the 3rd and 4th Qs.
Development agreement with Pfizer
EWING, N.J., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (ATRS) (“Antares”) today announced that it has entered into an agreement with Pfizer Inc. (“Pfizer”) to develop a combination drug device rescue pen. This rescue pen will utilize the Antares QuickShot® auto injector and an undisclosed Pfizer drug. Pfizer will pay for the development of the product and will be responsible for obtaining FDA approval of the combination product. The parties intend to enter into a separate supply agreement pursuant to which Antares will provide fully packaged commercial ready finished product to Pfizer at cost plus margin and Pfizer will then be responsible for commercializing the product in the United States, pending FDA approval. Antares will then receive royalties on net sales on the combination product.
“We are excited to begin our partnership with Pfizer, one of the world’s premier biopharmaceutical companies, on this important project to develop a rescue pen utilizing our QuickShot technology,” said Robert F. Apple, President and Chief Executive Officer of Antares. “This development agreement between Antares and Pfizer further expands our portfolio of pipeline partnered products. Additionally, it increases the potential number of products utilizing our innovative QuickShot auto injector technology platform. We look forward to working closely with Pfizer throughout the development phase of this combination product and assisting them with the FDA drug device approval process.”
Makena, Pfizer, sweet, now if we could only get XYO and the Bigfoot like Epi pen done we'd be 10 bucks a share.
Looks like there are only 2 sellers left on Amazon for the insole. 45 and 46 dollars with 5 shipping. I bet it's only while supplies last. It almost has to be Dr. Scholls. If we get a big pop on Dr Scholls news, my prediction is that RedZone will say he bought millions at .0027 and he's selling. LOL